Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25846216 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL25168328 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL30207467 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL23783057 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL25845553 | 0.80 | ALDH1A1 (0.63) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL29507768 | 0.80 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL853559 | 0.80 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL30928952 | 0.79 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL85672 | 0.79 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL1127011 | 0.79 | ALDH1A1 (0.73) | ALDH1A1KMT2ALMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4230/4885KMT2A 1429/4885LMNA 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.